Blueprint Medicines (NASDAQ:BPMC) Price Target Increased to $135.00 by Analysts at HC Wainwright

Blueprint Medicines (NASDAQ:BPMC) had its price objective hoisted by HC Wainwright from $125.00 to $135.00 in a research report sent to investors on Friday morning, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

A number of other equities analysts also recently issued reports on the company. JMP Securities reissued a market outperform rating and set a $114.00 target price on shares of Blueprint Medicines in a research note on Wednesday, April 10th. Citigroup raised their target price on Blueprint Medicines from $54.00 to $65.00 and gave the company a sell rating in a report on Friday, February 16th. Wedbush reiterated an outperform rating and issued a $110.00 price target on shares of Blueprint Medicines in a report on Friday, April 26th. Stifel Nicolaus raised their price objective on shares of Blueprint Medicines from $120.00 to $130.00 and gave the company a buy rating in a research note on Friday, April 26th. Finally, Barclays upped their target price on shares of Blueprint Medicines from $70.00 to $75.00 and gave the stock an equal weight rating in a research report on Friday. Three analysts have rated the stock with a sell rating, four have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of Hold and a consensus price target of $94.87.

Blueprint Medicines Stock Up 0.2 %

BPMC traded up $0.19 during trading on Friday, hitting $107.19. 1,004,153 shares of the stock were exchanged, compared to its average volume of 698,730. Blueprint Medicines has a 1-year low of $43.89 and a 1-year high of $110.93. The stock has a fifty day moving average price of $91.77 and a two-hundred day moving average price of $80.52. The company has a current ratio of 3.76, a quick ratio of 3.66 and a debt-to-equity ratio of 1.60.

Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) EPS for the quarter, topping the consensus estimate of ($2.04) by $0.22. The company had revenue of $71.96 million during the quarter, compared to analysts’ expectations of $67.34 million. Blueprint Medicines had a negative net margin of 102.15% and a negative return on equity of 215.07%. The business’s revenue was up 85.5% on a year-over-year basis. During the same quarter last year, the business earned ($2.65) EPS. As a group, sell-side analysts predict that Blueprint Medicines will post -5.41 earnings per share for the current year.

Insider Activity

In related news, Director Jeffrey W. Albers sold 25,073 shares of the firm’s stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $87.28, for a total transaction of $2,188,371.44. Following the completion of the sale, the director now directly owns 176,050 shares of the company’s stock, valued at approximately $15,365,644. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, EVP Tracey L. Mccain sold 5,194 shares of the stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $90.69, for a total transaction of $471,043.86. Following the completion of the transaction, the executive vice president now directly owns 60,498 shares in the company, valued at approximately $5,486,563.62. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Jeffrey W. Albers sold 25,073 shares of Blueprint Medicines stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $87.28, for a total transaction of $2,188,371.44. Following the completion of the sale, the director now owns 176,050 shares of the company’s stock, valued at approximately $15,365,644. The disclosure for this sale can be found here. Insiders have sold 92,289 shares of company stock worth $8,314,163 over the last 90 days. Company insiders own 3.88% of the company’s stock.

Institutional Investors Weigh In On Blueprint Medicines

Institutional investors have recently modified their holdings of the stock. PNC Financial Services Group Inc. raised its position in shares of Blueprint Medicines by 63.4% during the 3rd quarter. PNC Financial Services Group Inc. now owns 848 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 329 shares in the last quarter. Cutler Group LLC CA increased its position in Blueprint Medicines by 1,685.7% in the third quarter. Cutler Group LLC CA now owns 1,000 shares of the biotechnology company’s stock worth $50,000 after buying an additional 944 shares during the period. Compass Wealth Management LLC bought a new stake in Blueprint Medicines in the fourth quarter valued at $69,000. China Universal Asset Management Co. Ltd. grew its position in shares of Blueprint Medicines by 95.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,550 shares of the biotechnology company’s stock worth $78,000 after acquiring an additional 757 shares during the last quarter. Finally, Van ECK Associates Corp lifted its position in Blueprint Medicines by 28.4% in the 4th quarter. Van ECK Associates Corp now owns 872 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 193 shares during the last quarter.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.